European CHMP recommends approval of bulevirtide for treatment of chronic hepatitis delta virus (HDV) infection in compensated liver disease

Bulevirtide is an antiviral that blocks entry of hepatitis B virus and HDV into hepatocytes by binding to and inactivating NTCP, a bile salt liver transporter. Clinical trial data have demonstrated reduced HDV RNA levels and signs of liver inflammation in treated patients.


European Medicines Agency